Proton pump inhibitor (PPI) use is associated with an increased risk for gout, a population-based study finds.
Investigators propensity-score matched 20,138 adults with gout and 20,138 adults without gout from the Taiwan population. In adjusted analyses, esomeprazole users had a significant 1.3-fold increased risk for gout compared with individuals who did not use PPIs, Qiang Xu, MD, of The First Affiliated Hospital of Guangzhou University of Chinese Medicine in Guangzhou, China, and colleagues reported in the International Journal of Rheumatic Diseases. Omeprazole, pantoprazole, lansoprazole, and rabeprazole had no significant effect on gout risk.
Any use of PPIs within 30 days was significantly associated with 1.7-fold increased odds of gout compared with no PPI use. PPI use within 60, 90, and 120 days was significantly associated with 1.4-, 1.3, and 1.2-fold increased odds, respectively, the investigators reported.
Among patients who used PPIs within 30, 60, or 90 days, women had significantly greater odds of gout compared with men. Middle-aged adults 41-60 years had significantly greater odds of gout compared with those aged 61 years or older.
Dr Xu’s team urged caution in using PPIs in patients diagnosed with gout.
“These findings support the proper recognition and management of risk factors for PPI use in patients with gout. It is also necessary to recommend the development of effective drugs for patients with digestive issues and gout diseases.”
Zhu KJ, Feng W, Ma XN, et al. Proton pump inhibitor use associated with an increased risk of gout: A population-based case-control study. Int J Rheum Dis. Published online July 20, 2023. doi:10.1111/1756-185X.14834